NEW YORK (GenomeWeb News) – Empire Genomics today announced it has licensed a genomic biomarker from Cornell University for the development of a test to diagnose and determine treatment of patients with neuroendocrine prostate cancer, or NEPC.

Empire and Cornell will partner on developing a commercial grade assay and Empire plans to launch the NEPC test later this year. Empire also plans to seek a pharmaceutical partner to use the assay to accelerate patient stratification in clinical trials, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.